BMO Capital Markets Increases AbbVie (NYSE:ABBV) Price Target to $220.00
AbbVie (NYSE:ABBV – Free Report) had its price objective boosted by BMO Capital Markets from $214.00 to $220.00 in a report released on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Other equities analysts also recently issued research reports about the company. Piper Sandler Companies reiterated an “overweight” rating […]
More Stories
Critical Survey: Talen Energy (NASDAQ:TLN) and Centrica (OTCMKTS:CPYYY)
Talen Energy (NASDAQ:TLN – Get Free Report) and Centrica (OTCMKTS:CPYYY – Get Free Report) are both mid-cap oils/energy companies, but...
Head-To-Head Comparison: Navitas Semiconductor (NASDAQ:NVTS) versus Paragon ID (OTCMKTS:PAGDF)
Paragon ID (OTCMKTS:PAGDF – Get Free Report) and Navitas Semiconductor (NASDAQ:NVTS – Get Free Report) are both computer and technology...
Paramount Global (NASDAQ:PARA) Receives Average Recommendation of “Reduce” from Brokerages
Shares of Paramount Global (NASDAQ:PARA – Get Free Report) have been given a consensus rating of “Reduce” by the eighteen...
Analyzing Credo Technology Group (NASDAQ:CRDO) & Alphawave IP Group (OTCMKTS:AWEVF)
Alphawave IP Group (OTCMKTS:AWEVF – Get Free Report) and Credo Technology Group (NASDAQ:CRDO – Get Free Report) are both computer...
Reviewing DTE Energy (NYSE:DTE) and Spine Injury Solutions (OTCMKTS:SPIN)
DTE Energy (NYSE:DTE – Get Free Report) and Spine Injury Solutions (OTCMKTS:SPIN – Get Free Report) are both large-cap utilities...
SR Bancorp (SRBK) versus Its Peers Critical Review
SR Bancorp (NASDAQ:SRBK – Get Free Report) is one of 40 publicly-traded companies in the “Savings institutions, except federal” industry,...